CAMBRIDGE, Mass., Jan 12, 2004 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS) has
licensed its Hedgehog proteins and novel small molecule Hedgehog pathway
agonists (activators) to Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE),
for therapeutic applications in the treatment of neurological and other
disorders. The transaction is subject to compliance with applicable antitrust
laws. Under the terms of the agreement, Wyeth Pharmaceuticals will pay Curis a
license fee (in cash and equity), financial support for a minimum of two years
of Curis research dedicated to the program, and additional cash payments to
Curis upon the successful achievement of clinical development and drug approval
milestones. Wyeth Pharmaceuticals will also pay a royalty on net product sales
that escalates with increasing sales volume. Excluding product royalties, the
transaction has a potential value to Curis of more than $170 million, assuming
at least two products are successfully developed.

As part of the agreement, Curis has retained development and licensing options
for certain therapeutic applications of the Hedgehog activator technologies,
including those applications that qualify as orphan drug indications, topical
applications for hair growth, local delivery applications for treatment of
cardiovascular disease, and use of the technology with stem cells. Wyeth has an
option to acquire the orphan drug indications and the cardiovascular
applications, pending certain success criteria.

anders als INSG,die heute 135% zulegten wegen Zusammenarbeit mit IBM denke ich dass Curis mehr Potential besitzt.Die Zusammenarbeit mit Wyeth wird sich längerfristig lohnen